Development of transplant renal artery thrombosis and signs of haemolytic-uraemic syndrome following the change from cyclosporin to tacrolimus in a renal transplant patient.
Kiykim
Ahmet Alper
AA
Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Mersin, Turkey. aakiykim@yahoo.com
Ozer
Caner
C
Yildiz
Altan
A
Tiftik
Naci
N
Senli
Mehmet
M
Kelebek
Ebru
E
Doruk
Erdal
E
Akbay
Erdem
E
D000328:Adult; D000792:Angiography; D000800:Angioplasty, Balloon; D016572:Cyclosporine / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016030:Kidney Transplantation; D011994:Recombinant Proteins / Q000627:therapeutic use; D012077:Renal Artery / Q000000981:diagnostic imaging; D012078:Renal Artery Obstruction / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000628:therapy; D019233:Retreatment; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use; D013927:Thrombosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000628:therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D016572:Cyclosporine; D010959:Tissue Plasminogen Activator; D016559:Tacrolimus